- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04586907
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it.
This study will last up to about 19 weeks including screening period.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 138623
- Lilly Centre for Clinical Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are overtly healthy males or females not of childbearing potential, as determined through medical history and physical examination
- Contraceptive use by men should also be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Have a body mass index of 18.5 to 40 kilograms per square meter (kg/m²), inclusive
- Have hemoglobin A1c level of less than or equal to (≤)6.5 percent (%)
Patients with Type 2 Diabetes Mellitus (T2DM):
- Have T2DM for at least 6 months
- For Part A, have a hemoglobin A1c value at screening of 6.5% to 11% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening. For Part B, have hemoglobin A1c value at screening of 6.5% to 10% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening with or without 1 other OAM, such as DPP-IV inhibitors, SGLT-2 inhibitors, or sulfonylureas
Exclusion Criteria:
- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis
- Have a history of malignancy within 5 years prior to screening
- Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis
- Have evidence of significant active psychiatric disorder(s) as determined by the investigator
- Have undergone any form of bariatric surgery
- Have donated blood of 450 milliliters (mL) or more in the past 3 months or any blood donation within the past month from screening
- Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65 years) and 14 units per week (females and males above 65 years), or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge from the investigative site
- Smoke >10 cigarettes per day or the equivalent or are unable or unwilling to refrain from nicotine during investigative site admission
Patients with T2DM:
- Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
- Are currently treated with or within the past 3 months had treatment with GLP-1 receptor agonists, or insulin
- Have had severe hypoglycemic event in the last 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LY3537021 (Part A/Healthy)
LY3537021 administered subcutaneously (SC) to healthy participants.
|
Administered SC.
|
EXPERIMENTAL: LY3537021 (Part A/Type 2 Diabetes)
LY3537021 administered SC to participants with type 2 diabetes mellitus (T2DM).
|
Administered SC.
|
PLACEBO_COMPARATOR: Placebo (Part A)
Placebo administered SC.
|
Administered SC.
|
EXPERIMENTAL: LY3537021 (Part B/Healthy)
LY3537021 administered SC to healthy participants.
|
Administered SC.
|
EXPERIMENTAL: LY3537021 (Part B/Type 2 Diabetes)
LY3537021 administered SC to participants with T2DM.
|
Administered SC.
|
PLACEBO_COMPARATOR: Placebo (Part B)
Placebo administered SC.
|
Administered SC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline through Day 119 (Part A) and Day 57 (Part B)
|
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
|
Baseline through Day 119 (Part A) and Day 57 (Part B)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537021
Time Frame: Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)
|
PK: AUC of LY3537021
|
Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)
|
PK: Maximum Concentration (Cmax) of LY3537021
Time Frame: Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)
|
PK: Cmax of LY3537021
|
Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17730
- J2R-MC-YAAB (OTHER: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States